Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study
Abstract
:1. Introduction
2. Findings from the E.Pic.A Study
3. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Cardoso, F.; Kyriakides, S.; Ohno, S.; Penault-Llorca, F.; Poortmans, P.; Rubio, I.T.; Zackrisson, S.; Senkus, E. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2019, 30, 1194–1220. [Google Scholar] [CrossRef] [Green Version]
- Maltoni, R.; Casadio, V.; Ravaioli, S.; Foca, F.; Tumedei, M.M.; Salvi, S.; Martignano, F.; Calistri, D.; Rocca, A.; Schirone, A.; et al. Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer. Oncotarget 2017, 8, 16642–16649. [Google Scholar] [CrossRef] [Green Version]
- Maltoni, R.; Palleschi, M.; Ravaioli, S.; Tumedei, M.M.; Rocca, A.; Melegari, E.; Altini, M.; Puccetti, M.; Manunta, S.; Bravaccini, S. Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer. Cell Transpl. 2020, 29, 096368972092505. [Google Scholar] [CrossRef] [PubMed]
- Maltoni, R.; Fici, P.; Amadori, D.; Gallerani, G.; Cocchi, C.; Zoli, M.; Rocca, A.; Cecconetto, L.; Folli, S.; Scarpi, E.; et al. Circulating tumor cells in early breast cancer: A connection with vascular invasion. Cancer Lett. 2015, 367, 43–48. [Google Scholar] [CrossRef] [PubMed]
- Granato, A.M.; Frassineti, G.L.; Giovannini, N.; Ballardini, M.; Nanni, O.; Maltoni, R.; Amadori, D.; Volpi, A. Do Serum Angiogenic Growth Factors Provide Additional Information to That of Conventional Markers in Monitoring the Course of Metastatic Breast Cancer? Tumor Biol. 2006, 27, 302–308. [Google Scholar] [CrossRef]
- Bronte, G.; Ravaioli, S.; Bravaccini, S. What to look for in cell-free DNA from breast cancer patients. Breast Cancer Res. Treat. 2018, 170, 199–200. [Google Scholar] [CrossRef] [PubMed]
- Vasseur, A.; Kiavue, N.; Bidard, F.; Pierga, J.; Cabel, L. Clinical utility of circulating tumor cells: An update. Mol. Oncol. 2020, 15, 1647–1666. [Google Scholar] [CrossRef]
- Liu, T.; Hooda, J.; Atkinson, J.M.; Whiteside, T.L.; Oesterreich, S.; Lee, A.V. Exosomes in breast cancer–Mechanisms of Action and Clinical Potential. Mol. Cancer Res. 2021, 19, 935–945. [Google Scholar] [CrossRef]
- De Mattos-Arruda, L.; Siravegna, G. How to use liquid biopsies to treat patients with cancer. ESMO Open 2021, 6, 100060. [Google Scholar] [CrossRef] [PubMed]
- Fabian, C.J.; Kimler, B.F. Use of biomarkers for breast cancer risk assessment and prevention. J. Steroid Biochem. Mol. Biol. 2007, 106, 31–39. [Google Scholar] [CrossRef]
- Volpi, A.; Bravaccini, S.; Medri, L.; Cerasoli, S.; Gaudio, M.; Amadori, D. Usefulness of Immunological Detection of the Human Telomerase Reverse Transcriptase. Anal. Cell. Pathol. 2005, 27, 347–353. [Google Scholar] [CrossRef]
- Khatcheressian, J.L.; Hurley, P.; Bantug, E.; Esserman, L.J.; Grunfeld, E.; Halberg, F.; Hantel, A.; Henry, N.L.; Muss, H.B.; Smith, T.J.; et al. Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. J. Clin. Oncol. 2013, 31, 961–965. [Google Scholar] [CrossRef] [PubMed]
- Associazione Italiana di Oncologia Medica (AIOM). Linee Guida Neoplasie Della Mammella Edizione 2020. Available online: https://www.aiom.it/wp-content/uploads/2020/10/2020_LG_AIOM_Neoplasie_Mammella_16022021.pdf (accessed on 8 April 2021).
- Schreve, R.H.; Terpstra, O.T.; Ausema, L.; Lameris, J.S.; Van Seijen, A.J.; Jeekel, J. Detection of liver metastases. A prospective study comparing liver enzymes, scintigraphy, ultrasonography and computed tomography. Br. J. Surg. 2005, 71, 947–949. [Google Scholar] [CrossRef]
- Kemeny, M.M.; Sugarbaker, P.H.; Smith, T.J.; Edwards, B.K.; Shawker, T.; Vermess, M.; Jones, A.E. A Prospective Analysis of Laboratory Tests and Imaging Studies To Detect Hepatic Lesions. Ann. Surg. 1982, 195, 163–167. [Google Scholar] [CrossRef] [PubMed]
- Wiener, S.N. An Assessment of Routine Liver Scanning in Patients With Breast Cancer. Arch. Surg. 1978, 113, 126. [Google Scholar] [CrossRef]
- Chan, D.W.; Beveridge, R.A.; Muss, H.; Fritsche, H.A.; Hortobagyi, G.; Theriault, R.; Kiang, D.; Kennedy, B.J.; Evelegh, M. Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J. Clin. Oncol. 1997, 15, 2322–2328. [Google Scholar] [CrossRef] [PubMed]
- Emens, L.A.; Davidson, N.E. The follow-up of breast cancer. Semin. Oncol. 2003, 30, 338–348. [Google Scholar] [CrossRef]
- Nicolini, A.; Tartarelli, G.; Carpi, A.; Metelli, M.R.; Ferrari, P.; Anselmi, L.; Conte, M.; Berti, P.; Miccoli, P. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases. BMC Cancer 2006, 6, 269. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Valenzuela, P.; Mateos, S.; Tello, E.; López-Bueno, M.J.; Garrido, N.; Gaspar, M.J. The contribution of the CEA marker to CA 15.3 in the follow-up of breast cancer. Eur. J. Gynaecol. Oncol. 2003, 24, 60–62. [Google Scholar]
- Guadagni, F.; Ferroni, P.; Carlini, S.; Mariotti, S.; Spila, A.; Aloe, S.; D’Alessandro, R.; Carone, M.D.; Cicchetti, A.; Ricciotti, A.; et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: A prospective longitudinal study. Clin. Cancer Res. 2001, 7, 2357–2362. [Google Scholar] [PubMed]
- Guarneri, V.; Pronzato, P.; Bertetto, O.; Roila, F.; Amunni, G.; Bortolami, A.; Tognazzo, S.; Griguolo, G.; Pagano, E.; Stracci, F.; et al. Use of Electronic Administrative Databases to Measure Quality Indicators of Breast Cancer Care: Experience of Five Regional Oncology Networks in Italy. JCO Oncol. Pract. 2020, 16, e211–e220. [Google Scholar] [CrossRef] [PubMed]
- Massa, I.; Balzi, W.; Burattini, C.; Gentili, N.; Bucchi, L.; Nanni, O.; Gallegati, D.; Pierini, A.; Amadori, D.; Falcini, F.; et al. The challenge of sustainability in healthcare systems: Frequency and cost of inappropriate patterns of breast cancer care (the E.Pic.A study). Breast 2017, 34, 103–107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- NCCN: NCCN Clinical Practice Guidelines in Oncology—Breast Cancer, Version 1.2019. Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed on 8 April 2021).
Stage | Year | % | ||||
---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | Total | ||
0 | 22 | 23 | 13 | 40 | 98 | 6.5 |
I | 234 | 196 | 222 | 212 | 864 | 57.5 |
IIA | 77 | 73 | 85 | 84 | 319 | 21.2 |
IIB | 37 | 20 | 26 | 36 | 119 | 7.9 |
IIIA | 13 | 10 | 15 | 21 | 59 | 3.9 |
IIIB | 1 | 3 | 2 | 5 | 11 | 1 |
IIIC | 8 | 6 | 11 | 7 | 32 | 2 |
Total | 392 | 331 | 374 | 405 | 1502 | 100 |
Year (Patients) | 2015 (392) | 2016 (331) | 2017 (374) | 2018 (405) | Total (1502) | ||||
---|---|---|---|---|---|---|---|---|---|
Marker type | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 or CEA |
No. of exams | 486 | 352 | 464 | 156 | 641 | 158 | 656 | 161 | 3074 |
Total amount EUR | 9234 EUR | 3872 EUR | 8797 EUR | 1709 EUR | 12,179 EUR | 1738 EUR | 12,464 EUR | 1771 EUR | 51,764 EUR |
No. of patients with exams | 288 | 222 | 263 | 115 | 328 | 126 | 334 | 122 | 1222 |
% of patients with exams | 73 | 57 | 79 | 35 | 88 | 34 | 82 | 30 | 81 |
Tumor Stage 0 | |||||||||
---|---|---|---|---|---|---|---|---|---|
Year (patients) | 2015 (22) | 2016 (23) | 2017 (13) | 2018 (40) | Total (98) | ||||
Marker type | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 or CEA |
No. of exams | 12 | 10 | 11 | 7 | 5 | 3 | 16 | 9 | 73 |
Total amount EUR | 228 EUR | 110 EUR | 209 EUR | 77 EUR | 95 EUR | 33 EUR | 304 EUR | 99 EUR | 1155 EUR |
No. of patients with exams | 9 | 7 | 8 | 5 | 4 | 2 | 10 | 5 | 34 |
% of patients with exams | 41 | 32 | 35 | 22 | 31 | 15 | 25 | 13 | 35 |
Tumor Stage I | |||||||||
Year (patients) | 2015 (234) | 2016 (196) | 2017 (222) | 2018 (212) | Total (864) | ||||
Marker type | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 or CEA |
No. of exams | 316 | 229 | 292 | 99 | 403 | 92 | 359 | 65 | 1855 |
Total amount EUR | 6004 EUR | 2519 EUR | 5542 EUR | 1089 EUR | 7657 EUR | 1012 EUR | 6821 EUR | 715 EUR | 31,359 EUR |
No. of patients with exams | 189 | 144 | 165 | 71 | 206 | 73 | 189 | 55 | 750 |
% of patient with exams | 81 | 62 | 84 | 36 | 93 | 33 | 89 | 26 | 87 |
Tumor Stage IIA | |||||||||
Year (patients) | 2015 (77) | 2016 (73) | 2017 (85) | 2018 (84) | Total (319) | ||||
Marker type | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 or CEA |
No. of exams | 92 | 68 | 104 | 31 | 131 | 39 | 151 | 52 | 668 |
Total amount EUR | 1748 EUR | 748 EUR | 1976 EUR | 341 EUR | 2489 EUR | 429 EUR | 2869 EUR | 572 EUR | 11,172 EUR |
No. of patients with exams | 49 | 44 | 59 | 26 | 69 | 32 | 79 | 37 | 261 |
% of patient with exams | 64 | 57 | 81 | 36 | 81 | 38 | 94 | 44 | 82 |
Tumor Stage IIB | |||||||||
Year (patients) | 2015 (37) | 2016 (20) | 2017 (26) | 2018 (36) | Total (119) | ||||
Marker type | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 | CEA | CA15-3 or CEA |
No. of exams | 50 | 36 | 29 | 5 | 42 | 9 | 58 | 13 | 242 |
Total amount EUR | 950 EUR | 396 EUR | 551 EUR | 55 EUR | 798 EUR | 99 EUR | 1102 EUR | 143 EUR | 4094 EUR |
No. of patients with exams | 30 | 23 | 18 | 4 | 23 | 9 | 27 | 10 | 98 |
% of patient with exams | 81 | 62 | 90 | 20 | 88 | 35 | 75 | 28 | 82 |
Total amount for stage 0, I, IIA and IIB | 47,780 EUR |
Patient Number | Stage | Age At Surgery | Surgery Type | ER | PgR | Ki67/Mib1 | HER2 | Relapse Site | CEA (ug/L) | CA15-3 (KU/L) |
---|---|---|---|---|---|---|---|---|---|---|
1 | IIIA | 72 | M | 20% | 10% | 20% | 0 | Liver | NP | 56.8 |
2 | IIIC | 53 | Q | 0% | 0% | 67% | 0 | Axillary lymph node | Normal | Normal |
3 | IIA | 79 | M | 0% | 0% | 80% | 0 | Axillary lymph node | NP | 58.5 |
4 | IIA | 64 | M | 0% | 0% | 70% | 0 | Skin | Normal | Normal |
5 | IIIC | 49 | Q | 100% | 100% | 5% | 0 | Bones | NP | Normal |
6 | IIIB | 87 | M | 90% | 35% | 21% | 0 | Skin | NP | Normal |
7 | IIB | 51 | M | 0% | 0% | 75% | 0 | Brain | NP | Normal |
8 | IIIC | 72 | M | 100% | 0% | 25% | +++ | Liver | NP | Normal |
9 | IIB | 89 | Q | 50% | 10% | 40% | 0 | Bones | NP | Normal |
10 | IIIC | 84 | M | 0% | 0% | 30% | 0 | Axillary extension | NP | Normal |
11 | IIIA | 47 | M | 10% | 10% | 40% | 0 | Skin | NP | Normal |
12 | IIIB | 80 | M | 0% | 0% | 35% | 0 | Liver | NP | NP |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Maltoni, R.; Balzi, W.; Rossi, T.; Fabbri, F.; Bravaccini, S.; Montella, M.T.; Massa, I.; Bertoni, L.; Falcini, F.; Altini, M. Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study. Curr. Oncol. 2022, 29, 433-438. https://doi.org/10.3390/curroncol29020039
Maltoni R, Balzi W, Rossi T, Fabbri F, Bravaccini S, Montella MT, Massa I, Bertoni L, Falcini F, Altini M. Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study. Current Oncology. 2022; 29(2):433-438. https://doi.org/10.3390/curroncol29020039
Chicago/Turabian StyleMaltoni, Roberta, William Balzi, Tania Rossi, Francesco Fabbri, Sara Bravaccini, Maria Teresa Montella, Ilaria Massa, Lucia Bertoni, Fabio Falcini, and Mattia Altini. 2022. "Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study" Current Oncology 29, no. 2: 433-438. https://doi.org/10.3390/curroncol29020039
APA StyleMaltoni, R., Balzi, W., Rossi, T., Fabbri, F., Bravaccini, S., Montella, M. T., Massa, I., Bertoni, L., Falcini, F., & Altini, M. (2022). Appropriateness and Economic Analysis of Conventional Circulating Biomarkers Assessment in Early Breast Cancer: A Real-World Experience from the E.Pic.A Study. Current Oncology, 29(2), 433-438. https://doi.org/10.3390/curroncol29020039